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 Background Endogenous hormones and growth factors that increase mammographic breast density could increase ovarian 
cancer risk. We examined whether high breast density is associated with ovarian cancer risk.
 Methods We conducted a cohort study of 724 603 women aged 40 to 79 years with 2 506 732 mammograms participating in 
the Breast Cancer Surveillance Consortium from 1995 to 2009. Incident epithelial ovarian cancer was diagnosed 
in 1373 women. We used partly conditional Cox regression to estimate the association between breast density 
and 5-year risk of incident epithelial ovarian cancer overall and stratified by 10-year age group. All statistical tests 
were two-sided.
 Results Compared with women with scattered fibroglandular densities, women with heterogeneously dense and 
extremely dense breast tissue had 20% and 18% increased 5-year risk of incident epithelial ovarian cancer (haz-
ard ratio [HR] = 1.20, 95% confidence interval [CI] = 1.06 to 1.36; HR = 1.18, 95% CI = 0.93 to 1.50, respectively; 
Ptrend = .01). Among women aged 50 to 59 years, we observed a trend in elevated risk associated with increased 
breast density (Ptrend = .02); women with heterogeneously and extremely dense breast tissue had 30% (HR = 1.30; 
95% CI = 1.03 to 1.64) and 65% (HR = 1.65; 95% CI = 1.12 to 2.44) increased risk, respectively, compared with 
women with scattered fibroglandular densities. The pattern was similar but not statistically significant at age 40 
to 49 years. There were no consistent patterns of breast density and ovarian cancer risk at age 60 to 79 years.
 Conclusions Dense breast tissue was associated with a modest increase in 5-year ovarian cancer risk in women aged 50 to 
59 years but was not associated with ovarian cancer at ages 40 to 49 or 60 to 79 years.
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most risk factors identified for ovarian cancer are related to men-
strual and reproductive factors, lifestyle, and medical history (1–3). 
however, these factors explain little of the etiology of ovarian can-
cer, likely because of the heterogeneity of ovarian tumors (4). one 
unexplored potential risk factor is mammographic breast density, 
which is one of the strongest risk factors for breast cancer (5,6). 
Breast and ovarian cancers are both associated with endogenous 
and exogenous sex hormones and share similar risk and protective 
factors in their etiology (7,8).
It is plausible that circulating and tissue sex hormones that 
increase ovarian cancer risk are also associated with dense breast 
tissue. the underlying biologic mechanism resulting in high 
breast density and elevated breast cancer risk remains unclear. 
martin and Boyd suggest that breast density reflects cumulative 
exposure to factors that influence endogenous estrogen exposure; 
high exposure possibly affects cell division and predisposes breast 
tissue to genetic damage (9). As a marker of cumulative estrogen 
effect, breast density might also be a marker of ovarian cancer risk. 
ovarian cancer has hormonal etiology through androgens, estro-
gens, and gonadotropins (10). the prevailing hypothesis for the 
development of non-BRCA1/2 ovarian cancer focuses on increased 
number of ovulatory cycles and the hormones that influence men-
strual cycles (10,11).
Breast density is assessed on mammography by the amount 
of radiodense (or light) areas in epithelial tissue and stroma on a 
mammogram, often using the American College of radiology 
Breast Imaging reporting and Data System (BI-rADS) categories 
(12). Given the widespread assessment of breast density on rou-
tine screening mammography, breast density has the potential to 
be an easily identified risk factor for ovarian cancer. Nearly 75% 
of uS women aged 40  years or older report having had at least 
one mammogram (13), and women can know their breast density 
several years before the median age of ovarian cancer incidence at 
age 63 (14).
We evaluated the association between breast density and 5-year 
ovarian cancer risk among more than 700 000 women who received 
a mammogram in the Breast Cancer Surveillance Consortium 
(BCSC) (15), a national consortium of breast imaging registries. 
We also assessed whether the association was modified by known 
ovarian cancer risk factors.
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Methods
Study Cohort
the BCSC, a collaborative network of breast imaging registries 
(15), began in 1994 with the goal of assessing the delivery and qual-
ity of breast imaging and related patient outcomes in the united 
States. Data were obtained from the National Cancer Institute–
funded BCSC research resource (http://breastscreening.cancer.
gov/). Five BCSC registries were included in this analysis: Group 
health (Washington state), New hampshire mammography 
Network, New mexico mammography Project, San Francisco 
mammography registry, and Vermont Breast Cancer Surveillance 
System. mammography registries and the Statistical Coordinating 
Center each received 1)  institutional review board approval for 
active or passive consenting processes or a waiver of consent to 
enroll participants, link data, and perform analyses and 2) a Federal 
Certificate of Confidentiality and other protections for the identi-
ties of women, physicians, and facilities. All procedures were health 
Insurance Portability and Accountability Act compliant.
the study population was made up of women aged 40 to 
79 years who received at least one mammogram from which den-
sity was measured at a BCSC mammography facility during the 
period from 1995 to 2009. Women who self-reported at the time 
of the mammogram prior bilateral oophorectomy (n = 55 774) or 
who had a previous diagnosis of ovarian cancer (n = 1435) were 
excluded.
Measurement of Breast Density
mammographic breast density was assessed by the interpret-
ing radiologist as part of routine clinical care and reported on 
the American College of radiology BI-rADS scale as: 1, almost 
entirely fatty; 2, scattered fibroglandular densities; 3, heteroge-
neously dense; or 4, extremely dense (16). the primary analysis 
included both screening and diagnostic mammograms. the analy-
sis included all eligible mammograms for each woman.
Patient Characteristics
Self-administered patient questionnaires given at each mam-
mogram were used to ascertain age, race, ethnicity, parity status, 
current use of oral contraceptives and postmenopausal hormone 
therapy at the time of the mammogram, and family history of 
breast and ovarian cancer. Body mass index (BmI; kg/m2) was 
calculated from self-reported height and weight. menopausal sta-
tus was ascertained based on the questionnaire, and women were 
defined as postmenopausal if they reported natural menopause or 
were aged 55 years or older.
Ascertainment of Cancer and Mortality Outcomes
ovarian cancer diagnoses including stage and morphology were 
obtained by linkage to Surveillance, epidemiology, and end results 
(Seer) programs (for Group health, New mexico, and San 
Francisco) or to state cancer registries (for New hampshire and 
Vermont) (17). the primary outcome for analysis was incident epi-
thelial ovarian cancer or histology not otherwise specified (NoS) 
(International Classification of Diseases 9th and 10th editions; 
ICD-9 = 183 and ICD-10 = C56) (18) diagnosed within 5 years 
after mammography (n = 1373 cases). Diagnosis of breast cancer 
before the mammogram was based on self-report on the patient 
questionnaire or identification through linkage with cancer reg-
istries and pathology databases. Vital status was obtained through 
linkage to cancer registries and state vital statistics departments.
Statistical Analysis
We describe the distribution of risk factors at each woman’s first 
mammogram in BCSC by breast density category and ovarian 
cancer status within 5 years. We modeled 5-year risk of incident 
epithelial ovarian cancer using partly conditional Cox regression 
to account for potential correlation among repeated mammograms 
during the study period (19). models included each mammogram 
with a breast density measurement (mean = 3.2 mammograms per 
woman). hazard ratios (hrs) and 95% confidence intervals (CIs) 
were estimated. Standard errors are based on a robust sandwich 
estimator for repeated measures survival data (20). Follow-up began 
at the date of the mammogram and ended at the first of the fol-
lowing: ovarian cancer diagnosis, report of bilateral oophorectomy, 
death, or 5 years after the mammogram. models included indica-
tor variables for BI-rADS breast density categories relative to the 
most common category, scattered fibroglandular densities (21). 
We evaluated linear trends in hazard ratios by examining the Wald 
test P value for linear density categories. models were stratified 
on BCSC registry and adjusted for age (continuous in years), par-
ity status, current oral contraceptive use, current hormone therapy 
use, prior breast cancer diagnosis, and first-degree family history of 
breast or ovarian cancer. models in women age 40 to 49 years, 50 to 
59 years, and all ages were also adjusted for menopausal status. We 
selected factors for adjustment based on a priori assessment, exist-
ing literature, and the impact on the hazard ratios associated with 
breast density. to evaluate effect modification, we examined inter-
action terms between breast density and each risk factor using the 
Wald test. Again using a partly conditional Cox regression account-
ing for correlation within women, a priori covariates evaluated for 
effect modification were age, current oral contraceptive use, parity 
status, menopausal status, current hormone therapy use, and fam-
ily history of breast or ovarian cancer. oral contraceptive use was 
modeled as yes, no, or missing/unknown, given the large propor-
tion of missing data for this variable. the proportional hazards 
assumption was assessed by examining log–log plots. All statistical 
tests were two-sided, and a P value of less than .05 was considered 
statistically significant. Analyses were performed using Stata ver-
sion 12 (StataCorp, College Station, tX).
In sensitivity analyses, we 1) restricted the outcome to hormo-
nally responsive epithelial ovarian cancer [based on morphology 
codes for surface epithelial stromal tumors, including 802 carci-
noma undifferentiated NoS, 805 papillary carcinoma, 814 ade-
nocarcinoma NoS, 826 papillary adenocarcinoma, 831 clear cell 
adenocarcinoma, 838 endometroid adenocarcinoma, 844 cystad-
enocarcinoma NoS, 845 papillary cystadenocarcinoma NoS, 846 
papillary serous cystadenocarcinoma, 847 mucinous cystadenocar-
cinoma NoS, 848 mucinous adenocarcinoma, 857 adenocarcinoma 
with metaplasia, and 900 Brenner tumor malignant (22)]; 2) ran-
domly selected one mammogram for each woman; 3) adjusted for 
BmI ; 4) extended follow-up from 5 to 10 years to evaluate ovarian 
cancer risk; and 5) excluded exams from women with a prior breast 
cancer diagnosis.
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results
We identified 781 812 women eligible for inclusion into the 
study. With exclusions for report of prior bilateral oophorectomy 
and previous diagnosis of ovarian cancer, the final study sample 
included 724 603 women with 2 506 732 mammograms.
Characteristics of women differed by BI-rADS breast den-
sity category (table  1). the majority of women with extremely 
dense breasts were aged 40 to 49 years at their first mammogram 
in BCSC. Women with dense vs fatty breasts were more likely to 
use oral contraceptives and be Asian and less likely to be Black or 
Table 1. Characteristics obtained at the first breast density measurement for each woman by Breast Imaging Reporting and Data System 




BI-RADS 1, almost 
entirely fatty





BI-RADS 4,  
extremely dense
(n = 724 603) % (n = 69 150) % (n = 306 089) % (n = 276 710) % (n = 72 654) %
Age, y
 40–49 46.8 26.7 38.0 55.5 69.1
 50–59 27.7 28.2 30.1 26.7 21.5
 60–69 15.8 26.0 19.5 11.6 6.4
 70–79 9.7 19.1 12.4 6.1 3.1
Race/ethnicity
 White, non-Hispanic 73.4 70.7 74.3 73.3 72.4
 Black, non-Hispanic 2.3 3.4 2.4 2.1 1.6
 Asian 7.6 4.0 5.3 9.2 14.1
 Hispanic 13.6 17.2 14.6 12.8 9.5
 Other/mixed 3.1 4.7 3.4 2.7 2.3
 Missing* (6.7) (9.1) (7.0) (6.1) (5.6)
Body mass index, kg/m2
 <18.5 1.8 0.6 1.0 2.0 5.8
 18.5 to <25 46.5 20.8 37.3 55.7 72.6
 25 to <30 28.9 30.4 32.8 27.5 16.3
 ≥30 22.8 48.2 28.9 14.8 5.2
 Missing* (16.4) (17.7) (17.4) (15.7) (13.9)
Parity status
 Parous 82.6 86.6 86.1 80.4 72.4
 Nulliparous 17.4 13.4 13.9 19.6 27.6
 Missing* (13.1) (14.6) (13.7) (12.1) (12.7)
Menopausal status
 Premenopausal 45.8 23.1 36.4 55.7 70.2
 Postmenopausal 54.2 76.9 63.6 44.3 29.8
 Missing* (14.6) (12.9) (14.2) (15.6) (14.6)
Oral contraceptive use†
 Yes 2.9 1.3 2.1 3.8 4.7
 No 51.4 52.4 48.3 53.7 54.6
 Missing‡ 45.7 46.3 49.6 42.5 40.7
Hormone therapy use†
 Yes 18.6 17.4 19.8 18.5 14.5
 No 81.4 82.6 80.2 81.5 85.5
 Missing* (9.3) (8.4) (9.4) (9.6) (8.7)
Prior diagnosis of  
breast cancer
 Yes 3.4 3.7 3.9 3.1 2.5
 No 96.6 96.3 96.1 96.9 97.5
 Missing* (6.7) (6.8) (7.4) (5.9) (6.7)
First-degree family  
history of breast  
or ovarian cancer
 Yes 13.6 13.0 13.4 13.8 13.9
 No 86.4 87.0 86.6 86.2 86.1
 Missing* (4.5) (4.9) (4.1) (4.8) (4.6)
* Percentage of total.
† At time of mammogram.
‡ Retained in analysis.
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hispanic. Women with fatty vs dense breasts were more likely to be 
postmenopausal, parous, and overweight or obese (BmI ≥25 kg/m2).
Women diagnosed with ovarian cancer were more likely to be 
older (aged >60 years), white, current users of hormone therapy, 
postmenopausal, have a prior breast cancer diagnosis, and have a 
family history of breast or ovarian cancer (table 2). Women with 
ovarian cancer were less likely than noncase patients to be parous 
or current users of oral contraceptives. ovarian cancer case patients 
compared with non–case patient did not have a higher proportion 
of BI-rADS 3 or 4 breast density. Approximately 91.1% of ovar-
ian cancers had invasive morphology, and 8.9% were borderline 
tumors. the majority of ovarian cancers were diagnosed at regional 
or distant stage (81.6%; data not shown).
In a fully adjusted model combining all age groups (table 3), 
compared with women with scattered fibroglandular tissue, women 
with heterogeneously dense and extremely dense breast tissue had 
20% (hr = 1.20; 95% CI = 1.06 to 1.36) and 18% (hr = 1.18; 
95% CI = 0.93 to 1.50) increased 5-year risk of incident epithelial 
ovarian cancer, respectively. the trend across increasing categories 
of breast density was statistically significant (P = .01).
Table 2. Characteristics obtained at the first breast density meas-
urement for each woman by incident ovarian cancer status in the 
Breast Cancer Surveillance Consortium, 1995 to 2009
Characteristic





 40–49 27.4 46.8
 50–59 28.8 27.7
 60–69 26.1 15.8
 70–79 17.8 9.7
Race/ethnicity
 White, non-Hispanic 80.1 73.4
 Black, non-Hispanic 1.2 2.3
 Asian 4.3 7.6
 Hispanic 11.6 13.6
 Other/mixed 2.8 3.1
 Missing* (5.6) (6.7)
Body mass index, kg/m2
 <18.5 2.4 1.8
 18.5 to <25 44.6 46.5
 25 to <30 30.0 28.8
 ≥30 22.9 22.8
 Missing* (16.5) (16.4)
Parity status
 Parous 77.2 82.6
 Nulliparous 22.8 17.4
 Missing* (13.0) (13.1)
Menopausal status
 Premenopausal 25.4 45.8
 Postmenopausal 74.6 54.2
 Missing* (11.2) (14.6)
Oral contraceptive use†
 Yes 1.0 2.9
 No 39.3 51.4
 Missing‡ 59.7 45.7
Hormone therapy use†
 Yes 24.8 18.5
 No 75.2 81.5
 Missing* (10.5) (9.3)
Prior diagnosis of  
breast cancer
 Yes 8.0 3.4
 No 92.0 96.6
 Missing* (7.7) (6.7)
First-degree family  
history of breast or  
ovarian cancer
 Yes 18.7 13.5
 No 81.3 86.5
 Missing* (4.2) (4.5)
Breast density
 Almost entirely fat 10.9 9.5
 Scattered 10.9 9.5
 Heterogeneous 45.1 42.2
 Extremely dense 34.7 38.2
 Missing* (9.4) (10.0)
* Percentage of total.
† At time of mammogram.
Table 3. Five-year risk of incident epithelial ovarian cancer: adjusted 
hazard ratio (HR) and 95% confidence interval (CI) associated with 
Breast Imaging Reporting and Data System breast density category, 
overall and stratified by age group
Breast density
No. of ovarian 
cancer cases* HR† (95% CI)
All ages‡ 1022
Almost entirely fat 150 0.99 (0.82 to 1.20)
Scattered 565 1.00 (referent)
Heterogeneous 507 1.20 (1.06 to 1.36)
Extremely dense 116 1.18 (0.93 to 1.50)
Ptrend§ .01
Aged 40–49 y‡ 207
Almost entirely fat 10 1.04 (0.52 to 2.08)
Scattered 73 1.00 (referent)
Heterogeneous 120 1.30 (0.97 to 1.74)
Extremely dense 38 1.22 (0.78 to 1.91)
Ptrend§ .23
Aged 50–59 y‡ 314
Almost entirely fat 37 1.11 (0.76 to 1.62)
Scattered 146 1.00 (referent)
Heterogeneous 160 1.30 (1.03 to 1.64)
Extremely dense 47 1.65 (1.12 to 2.44)
Ptrend§ .02
Aged 60–69 y 335
Almost entirely fat 59 1.03 (0.77 to 1.40)
Scattered 188 1.00 (referent)
Heterogeneous 161 1.33 (1.06 to 1.67)
Extremely dense 19 0.79 (0.47 to 1.33)
Ptrend§ .19
Aged 70–79 y 290
Almost entirely fat 55 0.89 (0.65 to 1.21)
Scattered 197 1.00 (referent)
Heterogeneous 114 0.96 (0.76 to 1.20)
Extremely dense 16 0.99 (0.54 to 1.83)
Ptrend§ .82
* The number of case patients by density and age group sum to more than the 
total number of case patients because women with multiple mammograms 
can appear in multiple density and age groups.
† Hazard ratio, stratified by Breast Cancer Surveillance Consortium registry and 
adjusted for age, oral contraceptive use, hormone therapy use, parity status, 
prior diagnosis of breast cancer, and family history of breast or ovarian cancer 
in a first-degree relative.
‡ Additionally adjusted for postmenopausal status.
§ Two-sided Wald test.
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We assessed effect modification of the breast density–ovarian 
cancer association. Although the interaction between breast den-
sity and age in decades was not statistically significant (P = .21), 
we noted patterns by age group. Among women aged 40 to 
49  years, there was a non-statistically significant trend toward 
denser breast tissue being associated with elevated risk relative to 
women with scattered fibroglandular densities (table 3). Among 
women aged 50 to 59 years, we observed a trend in elevated risk 
associated with increased breast density (P  =  .02); women with 
heterogeneously and extremely dense breast tissue had 30% (95% 
CI = 1.03 to 1.64) and 65% (95% CI = 1.12 to 2.44) increased risk, 
respectively, compared with women with scattered fibroglandu-
lar densities. Women aged 60 to 69 years with heterogeneously 
but not extremely dense breasts were at elevated risk compared 
with those with scattered fibroglandular densities. At age 70 to 
79  years, we found no association between breast density and 
ovarian cancer risk.
We observed no statistically significant variation in the asso-
ciation between breast density and 5-year risk of epithelial ovar-
ian cancer by oral contraceptive use, hormone therapy use, BmI, 
parity status, menopausal status, or prior breast cancer. however, 
we detected statistically significant variation by family history of 
breast or ovarian cancer (Pinteraction =  .002). Among women with a 
family history, risk was 1.73-fold higher among women with fatty 
compared with scattered fibroglandular breast density (table  4). 
Among women without a family history, risk was not elevated in 
women with fatty breasts, whereas women with heterogeneously 
and very dense breast tissue had a statistically significantly increased 
risk of ovarian cancer of 25% and a non-statistically significantly 
increased risk of 14%, respectively, compared with scattered fibro-
glandular density. the average age of women with a family history 
of breast or ovarian cancer was 57.6 years, and the average age of 
women without a family history was 56.0 years.
of ovarian cancer case patients in the analysis, 90% were con-
sidered to have a hormonally responsive morphology. the most 
common of these morphologies were papillary serous cystadenocar-
cinoma, cystadenocarcinoma not otherwise specified, endometri-
oid adenocarcinoma, and adenocarcinoma not otherwise specified. 
We found no notable differences in results when restricting the 
outcome to ovarian cancer histology types that are primarily asso-
ciated with hormonal exposure. We also observed similar results 
when the models included one randomly selected mammogram 
per woman. Further, the results did not change appreciably when 
we adjusted for BmI, extended the length of follow-up to 10-year 
risk, or excluded exams from women with a prior breast cancer 
diagnosis.
Discussion
our findings demonstrate that breast density assessed on mam-
mography is a modest risk factor for being diagnosed with inci-
dent epithelial ovarian cancer within 5 years for women aged 50 
to 59 years; specifically, women with heterogeneously or extremely 
dense breast tissue are at increased risk compared with women 
with scattered fibroglandular densities. the associations between 
density and ovarian cancer risk in women aged 40 to 49 years and 
60 to 79 years were not consistent and largely not statistically sig-
nificant. to our knowledge, this is the first study to evaluate breast 
density as an ovarian cancer risk factor. Although the relative risks 
we observed in women in their 50s are of similar magnitude to 
known ovarian cancer risk factors (4), the absolute risk differences 
are likely small given the rarity of ovarian cancer. Prior research has 
also demonstrated that postmenopausal women with high breast 
density are at increased risk of breast cancer (23).
Women aged 50 to 59 years are transitioning through meno-
pause with the suppression of ovarian function. this crucial time is 
associated with increasing ovarian cancer risk (14). Breast density 
decreases with hormonal changes associated with menopause (24). 
Kelemen et  al. demonstrated that percentage density within the 
breast declines with increasing age within the transition, primarily 
among women in their 50s. our data show that women aged 50 
to 59 years with dense breasts vs scattered fibroglandular density 
have 30% to 65% increased risk of ovarian cancer within 5 years, 
during the age of greatest change in breast density. this is also the 
age when women are most likely to use postmenopausal hormone 
therapy, which can increase breast density and ovarian cancer risk 
(25). the use of estrogen-alone postmenopausal hormone therapy 
is more strongly associated with ovarian cancer risk than estrogen-
progestin therapy (26) Although we did not observe a statistically 
significant interaction between the effects of age and breast density 
on risk of ovarian cancer, we may have had insufficient statistical 
power to observe the interaction.
ovarian cancer risk has been associated with total number of 
ovulatory cycles and total time exposed to estrogen and other 
Table 4. Five-year risk of incident epithelial ovarian cancer: adjusted hazard ratio (HR) and 95% confidence interval (CI) associated with 
Breast Imaging Reporting and Data System (BI-RADS) breast density category by family history of breast or ovarian cancer*
Family history of 
breast or ovarian 
cancer†
Breast density
BI-RADS 1 BI-RADS 2 BI-RADS 3 BI-RADS 4
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
 Yes‡ 1.73 (1.21 to 2.48) 1.00 (referent) 1.04 (0.79 to 1.36) 1.32 (0.78 to 2.24)
 No§ 0.82 (0.66 to 1.02) 1.00 (referent) 1.25 (1.09 to 1.43) 1.14 (0.88 to 1.48)
* Hazard ratio stratified by Breast Cancer Surveillance Consortium registry and adjusted for age, oral contraceptive use, hormone therapy use, parity status, 
postmenopausal status, and prior diagnosis of breast cancer.
† Test for heterogeneity, two-sided P = .002.
‡ Trend test, two-sided P < .001.
§ Trend test, two-sided P = .40.
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hormones (10,11). Although breast density decreases with age and 
menopause (27), it is unclear how sex hormones contribute to these 
changes. In premenopausal women, circulating sex hormone bind-
ing globulin is associated with increasing percentage breast den-
sity (Ptrend = .02), and there is some suggestion of trend with serum 
estradiol (Ptrend  =  .08) (28). Similarly, in postmenopausal women, 
increasing breast density is associated with serum progesterone 
and sex hormone binding globulin but not estradiol or testosterone 
(29). thus, circulating levels of sex hormones are inconsistently 
associated with breast density, suggesting that the extent of breast 
density may only in part reflect changes in sex hormones over a 
woman’s lifetime and thus is an inadequate surrogate for lifetime 
exposure to estrogen or other hormones.
We observed variation in the association between breast den-
sity and ovarian cancer risk by family history of breast or ovar-
ian cancer. Among women with a family history, we found a 70% 
increased risk of ovarian cancer associated with fatty vs scattered 
fibroglandular breast tissue. In contrast, among women without a 
family history, we observed an elevated ovarian cancer risk only in 
women with heterogeneously dense breast tissue. Shared genetic 
factors may exist between family history, fatty breasts, and risk of 
ovarian cancer. We were unable to assess whether women in our 
study were BRCA1/2 carriers.
We conducted a large cohort study to examine the association 
between breast density and ovarian cancer risk with well-defined 
exposure variables and outcomes and the ability to adjust for 
important ovarian cancer risk factors. Few other studies have access 
to both breast density measures and ovarian cancer outcomes. 
Despite these strengths, there were limitations to our analysis in 
terms of assessment of exposure, length of follow-up, and outcome 
assessment. In general, BI-rADS breast density has good intraob-
server agreement, with kappas ranging from 0.72 to 0.90 (30–32), 
but only modest inter-rater agreement (kappa = 0.58) (30), which 
would bias our risk estimate toward the null. Continuous measures 
of breast density may be more reflective of ovarian cancer risk, but 
continuous measures are not available in usual clinical care. We had 
limited ability to estimate long-term associations between breast 
density and ovarian cancer. We limited follow-up for our primary 
analysis to 5 years after mammogram. Also, because we obtained 
information about oophorectomy only at the time of mammog-
raphy, the analysis might have included some women who had a 
bilateral oophorectomy after a mammogram and before censoring. 
our evaluation of ovarian cancer incidence within 5 years of each 
mammogram minimizes the potential bias. Finally, relatively new 
research suggests that the precursor lesions to ovarian cancer could 
begin in the fallopian tube (33). We were unable to include can-
cers of the fallopian tube or peritoneum in analyses because these 
data were not collected by the participating breast imaging regis-
tries. however, we did restrict our primary outcome for analysis 
to epithelial ovarian cancer cases, and in a sensitivity analysis, we 
restricted further to morphologic subtypes most strongly related to 
hormones with little difference in results.
this study was designed to examine whether mammographic 
breast density is a risk factor for ovarian cancer. Women in their 
50s with dense breasts demonstrated an increased 5-year risk of 
ovarian cancer that was not present in the older women. our results 
could be valuable for research studies of ovarian cancer prevention 
by replicating the association of breast density and ovarian cancer 
in women aged 50 to 59 years. expanding our understanding of 
ovarian cancer etiology beyond genetic predisposition is critical to 
better target ovarian cancer prevention.
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